EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD47 promotes myeloma cell growth through JAK – STAT3 / MYC signalling and is targetable by ruxolitinib

Omar Faruq iD, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D Schimmer, Hong Chang iD

British Journal of Haematology · 2026-11 · 209 (5) · 2034-2043

DOI: 10.1111/bjh.70736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 14.08.2026. Verfasst von Omar Faruq und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Pyrazoles, STAT3 Transcription Factor, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukemia and Lymphoma Society of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood. Here, we demonstrate for the first time that CD47 intrinsically promotes myeloma cell proliferation and survival by activating the JAK/STAT3–MYC (Janus kinase/signal transducer and activator of transcription 3 – MYC) signalling axis. CD47 overexpression increased cell growth, accelerated G1–M‐cell cycle progression and promoted anchorage‐independent colony formation, accompanied by elevated phosphorylation of STAT3 and upregulation of MYC , whereas CD47 knockdown produced the opposite effects. Transcriptomic analysis of patient datasets revealed that high CD47 expression was associated with enrichment of the JAK–STAT3 and MYC pathways, and CD47 levels positively correlated with STAT3 and MYC expression, suggesting a potential regulatory interplay among these molecules. Pharmacological inhibition using the JAK1/2 inhibitor ruxolitinib (Rux) decreased cell viability, induced apoptosis and suppressed STAT3 and MYC signalling. Moreover, Rux synergized with bortezomib in myeloma cell lines and primary patient samples but spared normal cells. Collectively, these findings identify CD47 as an oncogenic driver with an intrinsic signalling function in MM and highlight the CD47–STAT3–MYC axis as a promising therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPyrazolesSTAT3 Transcription FactorProto-Oncogene Proteins c-mycSignal TransductionCD47 AntigenJanus KinasesHumansPyrimidinesNitrilesCell ProliferationCell Line, TumorJanus Kinase 1ApoptosisBortezomib

Stichwörter der Autor:innen

CD47STAT3c‐MYCmultiple myeloma (MM)ruxolitinib (Rux)

Substanzen

ruxolitinibPyrazolesSTAT3 Transcription FactorProto-Oncogene Proteins c-mycPyrimidinesNitrilesCD47 AntigenMYC protein, humanSTAT3 protein, humanCD47 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Laboratory Medicine Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

ORCID-Profile: Omar Faruq, Hong Chang

Förderung

  • Leukemia and Lymphoma Society of Canada

Zitieren

APA

Faruq, O., Iyer, D., Wang, P., Shrestha, M., Wei, C., Schimmer, A. D., & Chang, H. (2026). CD47 promotes myeloma cell growth through JAK – STAT3 / MYC signalling and is targetable by ruxolitinib. British Journal of Haematology, 209(5), 2034-2043. https://doi.org/10.1111/bjh.70736

Vancouver

Faruq O, Iyer D, Wang P, Shrestha M, Wei C, Schimmer AD, et al. CD47 promotes myeloma cell growth through JAK – STAT3 / MYC signalling and is targetable by ruxolitinib. British Journal of Haematology. 2026;209(5):2034-2043. doi:10.1111/bjh.70736

BibTeX
@article{Faruq2026,
  author = {Faruq, Omar and Iyer, Deepak and Wang, Patrick and Shrestha, Mariusz and Wei, Cuihong and Schimmer, Aaron D and Chang, Hong},
  title = {CD47 promotes myeloma cell growth through JAK – STAT3 / MYC signalling and is targetable by ruxolitinib},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2034--2043},
  doi = {10.1111/bjh.70736}
}
Kostenlos starten →